The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
Open accessAbstract
The central nervous system (CNS) is the major area that is affected by aging. Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment. Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process. On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochemical and structural differences between CNS and non-CNS drugs may assist both research areas. Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena. Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compounds, we analyzed the physicochemical property and the chemical structural profiles of 317 CNS and 626 non-CNS oral drugs. The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process. A list of substructural units that may be useful for CNS drug design was also provided here. A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs. The combined analysis provided the following guidelines for designing high-quality CNS drugs: (i) topological molecular polar surface area of <76 Å(2) (25-60 Å(2)), (ii) at least one (one or two, including one aliphatic amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) volume of 740-970 Å(3), (vi) solvent accessible surface area of 460-580 Å(2), and (vii) positive QikProp parameter CNS. The ranges within parentheses may be used during lead optimization. One violation to this proposed profile may be acceptable. The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc9800071 · Cited by 3,068
Self-citationStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Meyer, H. (1899) · Archiv für Experimentelle Pathologie und Pharmakologie · doi:10.1007/bf01834479 · Cited by 1,014
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9804011 · Cited by 627
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches
Cardoso, F. L., Brites, D., & Brito, M. A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.003 · Cited by 569
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980402t · Cited by 519
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Drug delivery to the central nervous system: a review.
Misra, A. R., Ganesh, S. D., Shahiwala, A., & Shah, S. P. (2003) · PubMed · Cited by 441
Hansch, C., Björkroth, J. P., & Leo, A. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760902 · Cited by 438
Drug and Gene Delivery to the Brain
Pardridge, W. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01054-1 · Cited by 405
Drug delivery to the central nervous system: A review
Tamargo, R. J., & Brem, H. (1992) · Neurosurgery Quarterly · Cited by 369
The p KaDistribution of Drugs: Application to Drug Discovery
Manallack, D. T. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100003 · Cited by 354
n, F. (1943) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-194302000-00025 · Cited by 347
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Computational approaches to the prediction of the blood–brain distribution
Norinder, U., & Haeberlein, M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00005-4 · Cited by 305
Hydrogen Bonding. 33. Factors That Influence the Distribution of Solutes between Blood and Brain
Abraham, M. H., Chadha, H. S., & Mitchell, R. C. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830915 · Cited by 301
Goodman and Gilman's The Pharmacological Basis of Therapeutics.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-502_5 · Cited by 190
Progress in understanding the structure–activity relationships of P-glycoprotein
Stouch, T. R., & Gudmundsson, O. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00006-6 · Cited by 181
Ghose, A. K., Herbertz, T., Pippin, D. A., Salvino, J. M., & Mallamo, J. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800475y · Cited by 166
Self-citationAdenot, M., & Lahana, R. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034205d · Cited by 144
Iyer, M., Mishra, R. K., Han, Y., & Hopfinger, A. J. (2002) · Pharmaceutical Research · doi:10.1023/a:1020792909928 · Cited by 142
On the Partition of Ampholytes: Application to Blood–Brain Distribution
Abraham, M. H., Takács‐Novák, K., & Mitchell, R. C. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960328j · Cited by 141
Lee, A. C., & Crippen, G. M. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900209w · Cited by 134
Colabufo, N. A., Berardi, F., Cantore, M., Contino, M., Inglese, C., Niso, M., & Perrone, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900743c · Cited by 127
Overton, E. (1897) · Zeitschrift für Physikalische Chemie · doi:10.1515/zpch-1897-2220 · Cited by 87
Knowledge-based chemoinformatic approaches to drug discovery
Ghose, A. K., Herbertz, T., Salvino, J. M., & Mallamo, J. P. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.012 · Cited by 72
Self-citationStrategies to optimize the brain availability of central nervous system drug candidates
Wager, T. T., Villalobos, A., Verhoest, P. R., Hou, X., & Shaffer, C. L. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.564158 · Cited by 54
Forecasting the Cost of U.S. Health Care in 2040
Fogel, R. W. (2008) · Journal of Policy Modeling · doi:10.1016/j.jpolmod.2009.05.004 · Cited by 49
Computational Prediction of Blood-brain Barrier Permeation
Clark, D. E. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40026-3 · Cited by 47
Rishton, G. M., LaBonte, K., Williams, A. J., Kassam, K., & Kolovanov, E. A. (2006) · PubMed · Cited by 40
Model-Free Drug-Likeness from Fragments
Ursu, O., & Oprea, T. I. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100202p · Cited by 37
Hegde, S. G., & Schmidt, M. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45028-9 · Cited by 15
Cited by
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Xiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Metadata
- Authors
- Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-11-15
- Volume
- 3
- Issue
- 1
- Pages
- 50-68
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2021431618
- Cited by
- 447
- References
- 46
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.